ArticleCureus2025
Three-Year Outcomes of iStent Inject W Implantation Combined With Phacoemulsification in Japanese Eyes With Open-Angle Glaucoma: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Twelve-Month Outcomes of iStent Infinite in Severe Open-Angle Glaucoma Compared with iStent Inject W in Mild-to-Moderate Disease.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Glaucoma is a leading cause of irreversible blindness. In Japan, most primary open-angle glaucoma (POAG) cases are normal-tension glaucoma (NTG). Micro-invasive glaucoma surgery (MIGS) such as the iStent inject W (Glaukos Corporation, San Clemente, CA) offers a less invasive option, but long-term outcomes in NTG-predominant populations are scarce. Objective The objective of this study is to evaluate three-year outcomes of combined phacoemulsification and iStent inject W implantation in Japanese eyes with POAG. Methods This retrospective study included 24 eyes from 14 Japanese patients undergoing combined surgery between February 2021 and May 2022 at Chutoen General Medical Center. Eyes with prior glaucoma surgery (except laser trabeculoplasty) or secondary glaucoma were excluded. Intraocular pressure (IOP) and medication scores were recorded up to 36 months postoperatively. Changes from baseline were analyzed with the Wilcoxon signed-rank test. Results Mean IOP decreased from 16.71 ± 4.54 mmHg to 12.63 ± 2.59 mmHg at 36 months (p < 0.001), 24% reduction. Medication scores decreased from 3.17 ± 1.55 to 1.42 ± 1.10 (p < 0.001). At 36 months, out of 24 eyes, eight eyes (33.3%) were medication-free, and 14 eyes (58.3%) achieved ≥20% IOP reduction. No additional glaucoma surgeries were required. Complications were minimal, with transient hyphema in two eyes (8.3%) and transient IOP elevation at one week in two eyes (8.3%). Conclusion iStent inject W combined with phacoemulsification provided safe and sustained IOP and medication reduction over three years in Japanese eyes with POAG, supporting its use in NTG-predominant populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.